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Background: We assessed the influence of atorvastatin on selected indicators of an inflammatory condition, left
ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy (DCM).
Methods: We included 68 DCM patients with left ventricular ejection fraction (LVEF) ≤40% treated optimally in a
prospective, randomized study. They were observed for 5 years. Patients were divided into two groups: patients who
were commenced on atorvastatin 40 mg daily for two months followed by an individually matched dose of 10 or
20 mg/day (group A), and patients who were treated according to current recommendations without statin therapy
(group B).
Results: After 5-year follow-up we assessed 45 patients of mean age 59 ± 11 years - 22 patients in group A (77% male)
and 23 patients in group B (82% male). Interleukin-6, tumor necrosis factor alpha, and uric acid concentrations were
significantly lower in the statin group than in group B (14.96 ± 4.76 vs. 19.02 ± 3.94 pg/ml, p = 0.012; 19.10 ± 6.39 vs.
27.53 ± 7.39 pg/ml, p = 0.001, and 5.28 ± 0.48 vs. 6.53 ± 0.46 mg/dl, p= 0.001, respectively). In patients on statin therapy a
reduction of N-terminal pro-brain natriuretic peptide concentration (from 1425.28 ± 1264.48 to 1098.01 ± 1483.86 pg/ml,
p= 0.045), decrease in left ventricular diastolic (from 7.15 ± 0.90 to 6.67 ± 0.88 cm, p= 0.001) and systolic diameters (from
5.87 ± 0.92 to 5.17 ± 0.97, p = 0.001) in comparison to initial values were observed. We also showed the significant increase
of LVEF in patients after statin therapy (from 32.0 ± 6.4 to 38.8 ± 8.8%, p = 0.016). Based on a comparison of curves using
the log-rank test, the probability of survival to 5 years was significantly higher in patients receiving statins (p= 0.005).
Conclusions: Atorvastatin in a small dose significantly reduce levels of inflammatory cytokines and uric acid, improve
hemodynamic parameters and improve 5-year survival in patients with DCM.
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According to the European Society of Cardiology (ESC),
dilated cardiomyopathy (DCM) is recognized based on
dilation and systolic dysfunction of the left ventricle, un-
less a patient simultaneously suffers from coronary ar-
tery disease (CAD), hypertension, valvular heart disease* Correspondence: agatbiel7@poczta.onet.pl; maciejbanach@aol.co.uk
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distribution, and reproduction in any mediumor congenital heart disease which is so significant that it
leads to an observed pathology of the myocardium [1].
DCM occurs more frequently in men and is most
common between the ages of 20 and 60 years [1,2].
About 1 in 3 cases of congestive heart failure (CHF) is
due to DCM. Despite treatment, CHF is a progressive
disease with high morbidity and mortality, suggesting
that important pathogenic mechanisms remain active
and unmodified by currently available treatment [1,2].
The cause of mortality in these patients is either end-
organ dysfunction due to pump failure or arrhythmia-ed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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dence has been presented indicating that autoimmunologic
processes, cellular as well as humoral ones, are involved in
the pathogenesis of dilated cardiomyopathy [3]. The com-
mon presence of viral genetic material in the myocardium
of patients with DCM provides the most compelling evi-
dence, but proof of causality is still lacking [3,4]. In ad-
dition, autoimmune reactions have been described in many
studies, indicating them as an important etiologic factor
[3,4]. A pivotal role for autoimmunity in a substantial pro-
portion of patients with DCM is supported by the presence
of organ-specific autoantibodies, inflammatory infiltrates
and pro-inflammatory cytotoxic cytokines [3-6]. Further-
more, familial occurrence of DCM has been described in
about 20–30% of cases, with the presence of autoantibodies
and abnormal cytokine profiles in first-degree relatives with
asymptomatic left ventricular enlargement [3,4]. This sug-
gests the involvement of a disrupted humoral and cellular
immunity early in the development of the disease [3,4].
Despite their lipid-lowering and anti-atherosclerotic
effects statins have also important pleiotropic properties.
They limit signal transmission from membrane receptors
and slow down pathologic remodeling of the heart and
vessels, inhibit the action of angiotensin II, inhibit apop-
tosis, improve endothelial function, retard the progression
of heart failure symptoms, reduce the level of N-terminal
pro-brain natriuretic peptide (NT-proBNP), restore auto-
nomic nervous system balance and might have a protec-
tive influence on renal function and blood pressure [7,8].
Previous studies have demonstrated that statins reduce
vascular and myocardial oxidative stress by inhibiting Rac-
induced nicotinamide adenine dinucleotide phosphatase
(NADPH) oxidase activity and reducing oxidized low
density lipoprotein (LDL) concentration by activated
monocyte-derived macrophages [9]. They also reduce
intracellular reactive oxygen species (ROS) in endothelial
cells by S-nitrosylation of thioredoxin [9,10].
The Rosuvastatin Impact on Ventricular Remodelling
Lipids and Cytokines (UNIVERSE), Controlled Rosuvastatin
Multinational Trial in Heart Failure (CORONA), and Effect
of rosuvastatin in patients with chronic heart failure
(GISSI-HF) trials did not indicate a significant role for
statins in HF patients, although the drug did reduce the
number of cardiovascular (CV) hospitalizations in the
CORONA trial [11-13]. Although mentioned prospective
studies using hydrophilic rosuvastatin showed no beneficial
effect on mortality, Vrtovec et al. reported that atorvastatin
therapy reduced the incidence of sudden cardiac death in
patients with advanced CHF [14]. Correale et al. evaluated
the effect of statin therapy on left ventricular dysfunction in
patients with CHF and showed that they had fewer read-
missions for adverse events, blunted inflammatory ac-
tivation and improved left ventricular performance assessed
by tissue Doppler imaging [15]. Metabolic and cardiaceffects may differ between the lipophilic and hydrophilic
statins [16].
Therefore the aim of our study was to assess the asso-
ciation between 5-year atorvastatin therapy and indica-
tors of an inflammatory condition and clinical outcomes
in patients with DCM.
Methods
Study population
In a prospective study, 68 patients with DCM (according to
the 2008 European Society of Cardiology [ESC] classifica-
tion) of either sex, aged 18 years or older with left ventricu-
lar ejection fraction (LVEF) ≤40% treated with optimal
medical therapy, were followed for 5 years [17,18]. Mean
disease duration was 7.5 ± 1.9 years. No patients had signifi-
cant coronary artery disease (>30% stenosis) as determined
by cardiac catheterization performed within a year before
the enrolment [19,20]. Arterial hypertension was not diag-
nosed in any of the patients. Date of death was ascertained
by questioning relatives or patients’ general practitioners
and estimated as close as possible to half year frames. Pa-
tients were randomized to one of two groups: A – patients
who were commenced on atorvastatin 40 mg daily for 2
months followed by an individually matched dose of 10 or
20 mg/day; and B – patients who were treated according to
current guidelines [21] without statin therapy.
The exclusion criteria were as follows: blood pressure
(BP) ≥140/90 or <90/60 mmHg; congenital heart disease;
acquired valvular disease with the exception of mitral
incompetence secondary to left ventricular dilatation;
persistent hyperactivity of aminotransferases with an unex-
plained etiology; muscle disorders which might cause drug-
induced myopathy; uncontrolled diabetes; liver diseases,
creatinine level >2 mg/dl and/or glomerular filtration rate
(GFR) <30 ml/min; alcohol or drug abuse; chronic inflam-
matory diseases, pregnancy or lactation, severe hypothy-
roidism, immunosuppressive treatment, operation or severe
injury during the month prior to blood collection, and pa-
tients who did not provide written informed consent.
Initial and control tests included full clinical examination
with the assessment of body mass index (BMI) and New
York Heart Association (NYHA) class, routine laboratory
tests, measurement of TNF-α, interleukin 6 (IL-6), and
transforming growth factor beta (TGF-β) concentrations in
blood plasma, measurement of N-terminal pro-brain natri-
uretic peptide (NT-proBNP), syndecan-4, cystatin C (CysC)
concentration in blood serum, echocardiographic examin-
ation and the assessment of exercise capacity in 6-min walk
test (6MWT). The frequency of HF hospitalization and
mortality were recorded during the 5-year follow-up period.
Consent from the Bioethics Commission of the Medical
University of Lodz (No. RNN/520/10/KB) was obtained.
Written informed consent was obtained from all
the patients.
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Blood glucose was measured with a glucose dehydrogenase
method after precipitation of proteins by trichloroacetic
acid. LDL and high-density lipoprotein (HDL) fractions
were separated from fresh serum by combined ultracentri-
fugation and precipitation. Lipoprotein fraction cholesterol
and triglycerides were measured enzymatically. The con-
centration of NT-proBNP was determined using an Elecsys
2010 analyzer (Roche Diagnostics, Warsaw, Poland). After
the blood was taken, the material was centrifuged; the
obtained serum was frozen at the temperature of −70°C
and stored in this condition until the time of examination.
The determination of NT-proBNP in blood serum was
performed with the electroluminescence method with 2
polyclonal antibodies directed against NT-proBNP within
epitope 1 (1–21 amino acid sequence) and epitope 2 (39–
50 amino acids). Concentration values are given in pg/ml.
Determination of IL-6 and TNF-α was performed with re-
agents of Beckman Coulter (Paris, France), using a sand-
wich ELISA assay. Measurement of CysC was performed
using immunonephelometric assay for the quantitative
measurement of this marker in human serum and hepa-
rinized plasma. Diazyme’s Cystatin C assay is based on the
latex-enhanced immunoturbidimetric method. The range
of valid values for CysC measured by the immuno-
nephelometric method (N Latex Cystatin C test) is 0.53–
0.95 mg/l. Determination of syndecan 4 was performed
with reagents of USCN Life Science Inc. (Wuhan, China),
using a sandwich ELISA assay [19]. Determination of
TGF-β was performed with reagents of Diaclone/Gen-
Probe (San Diego, USA), using an enzyme-linked im-
munosorbent assay.
Echocardiographic assessment
Echocardiography was performed using an ALOKA Alpha
6 Premier (Tokyo, Japan) with a 3–11 MHz probe. Left
ventricular (LV) systolic function and cardiac dimensions
indexed to body surface area were determined. The heart
was imaged in parasternal short axis view to obtain LV wall
thickness and parasternal long axis view to measure ejec-
tion fraction (EF), which was determined with Simpson’s
rule: EF = (LVEDV-LVESV)/LVEDV, where LVEDV is left
ventricular end-diastolic volume and LVESV is left ven-
tricular end-systolic volume.
Left ventricular end-diastolic diameter (LVEDD) and left
ventricular end-systolic diameter (LVESD) were measured
from M-mode tracings. Flow parameters were assessed in
Doppler examination (continuous, pulsatile and color).
Quantification of LV systolic function was also made
through application of:
A. The myocardial performance index (MPI), which
reflects global efficiency of LV functioning. It is
determined by dividing the sum of isovolumetricrelaxation time and isovolumetric contraction time
by ejection time. The time of isovolumetric
contraction is measured from the closure of the
mitral valve to the opening of the aortic valve.
The time of isovolumetric relaxation is measured
from the closure of the aortic valve to the opening
of the mitral valve. The norm is ≤0.4; higher
values indicate deteriorating efficiency of the
myocardium [20].
B. Rate of systolic pressure change in the left ventricle
(dP/dT). This index determines the increase in
systolic pressure generated by the LV in time
calculated using continuous wave (CW) Doppler
based on the time of increase in the speed of mitral
regurgitation (MR) from 1 to 3 m/s. Values of dP/dT
<400 mmHg/s indicate that the systolic function of
the LV is significantly impaired; normal values are
>2000 mmHg/s [20,22].
Diastolic function of the LV was assessed using the pa-
rameters of mitral inflow registered with pulsed wave
(PW) Doppler in 4-cavity apical projection and diastolic
speed values of movement of the mitral ring registered
with tissue Doppler imaging.Statistical analysis
The STATISTICA software package 9 (StatSoft, Poland)
was used for analysis. All values presented are the mean
or median ± standard deviation (SD) for continuous vari-
ables and the percentage of total patients for categorical
variables. The Shapiro-Wilk test was used to assess the
normality of distribution. To compare groups Student’s
t test or 2-way analysis of variance (ANOVA) for con-
tinuous and discrete variables with normal distribution
and non-parametric Mann-Whitney U test if the distri-
bution was not normal were applied. For categorical var-
iables chi-square test or Fisher’s test for small samples
was applied for comparisons. For quantitative variables
(continuous and discrete) to check correlations between
variables Spearman’s rank correlation coefficient was used.
The assessment of factors influencing prognosis in patients
with DCM was performed using single-factor logistic re-
gression and the forward stepwise regression model, and
receiver operating characteristic (ROC) curves and the for-
ward stepwise regression model. Based on analysis of the
ROC curve, cut-off points were found for the measurable
variables by estimating the highest product of sensitivity
and specificity. Calculations and drawings were made using
SPSS 17.0 statistical package. The analysis of death was
plotted using the Kaplan-Meier method. Date of death was
ascertained by questioning relatives or patients’ general
practitioners and estimated as close as possible to half year
frames. Results were considered significant at p < 0.05.
Table 1 Characteristics of the analyzed patients with
DCM after 5 years
PARAMETER Mean ± SD or number of patients (%)
Age (years) 59.0 ± 11.0












LV diastolic dysfunction 4 (9)











Loop diuretics 41 (91)
Spironolactone/eplerenone 39 (87)
vBeta-blockers 40 (88)
ACE inhibitors 41 (91)






Oral hypoglycemics 4 (9)
*Anemia: Hb (g/dL) <13 in men and <12 in women.
ABBREVIATIONS: ACE inhibitors – angiotensin converting enzyme inhibitors;
ARB angiotensin receptor blocker; MR mitral regurgitation; NYHA New York
heart association; sPAP systolic pulmonary artery pressure; TR
tricuspid regurgitation.
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Baseline characteristics of the patients
During 5-year observation 29% (n = 20) of all 68 patients
died, 41% (n = 28) required one re-hospitalization and
6% (n = 4) two re-hospitalizations because of HF decom-
pensation. In 9% (n = 6) cardiac resynchronization ther-
apy was applied, mitral and tricuspid valvuloplasty was
performed in 1 person and heart transplantation in 2
people (these patients were excluded from the analysis
to avoid the imposition of the effect of statins and the
results of such procedures).
Finally after 5 years we assessed 45 patients of mean
age 59 ± 11 years (5 females and 40 males): group A– 22
patients (77% male) of mean age 63 ± 10 years treated
with atorvastatin in individual dose of 10 (n = 11) or
20 mg (n = 11), and group B – 23 patients (82% male) of
mean age 57 ± 13 years without statin therapy. In 36%
(n = 16) of patients we observed dyspnea, pulmonary
hemostasis in 11% (n = 5), and edema in 9% (n = 4). Body
mass assessment revealed underweight in 4% (n = 2) of
patients, normal weight in 36% (n = 16), overweight in
24% (n = 11) and obesity in 36% (n = 16). Chronic ob-
structive pulmonary disease was present in 4% (n = 2)
and diabetes mellitus (DM) or abnormal glucose level in
20% (n = 9) of patients. The detailed characteristics of
the patients are presented in Table 1.
The influence atorvastatin treatment on inflammatory
and clinical parameters
In group A compared to group B, IL-6 concentration
was considerably lower (14.96 ± 4.76 vs 19.02 ± 3.94 pg/ml,
p = 0.011) after five years of treatment with atorvastatin.
TNF-α levels were also significantly reduced in the statin
group than in Group B (19.10 ± 6.39 vs 27.53 ± 7.39 pg/ml,
p = 0.001). Also uric acid (UA) concentration was lower
in the atorvastatin group (5.28 ± 0.48 vs 6.53 ± 0.46 mg/dl,
p = 0.001). No significant differences concerning NT-
proBNP concentration, echocardiographic parameters of
the left ventricle, distance on 6MWT and in functional
classification according to NYHA were observed between
examined groups. The detailed comparison between groups
A and B is presented in Table 2.
Patients with and without atorvastatin therapy –
comparing changes over time
In the statin group after 5 years a decrease in NT-
proBNP concentration compared with initial values from
1425.28 ± 1264.48 to 1098.01 ± 1483.86 pg/ml (p = 0.045)
and a decrease in LVdD and LVsD from 7.15 ± 0.90 to
6.67 ± 0.88 cm (p = 0.001) and from 5.87 ± 0.92 to 5.17 ±
0.97 (p = 0.001), respectively, were achieved. The signifi-
cant increase of LVEF from 32.0 ± 6.4 to 38.8 ± 8.8% (p =
0.0164) was also observed in Group A. There were no sig-
nificant changes in the range of these parameters inGroup B. Only in the atorvastatin group a significant re-
ductions of total cholesterol (from 207 ± 71 to 183 ±
69 mg/dL) and LDL cholesterol (from 116 ± 36 to 80 ±
25 mg/dL) were observed.
In the control group a significant increase in TNF-α
levels from 12.70 ± 12.78 to 27.50 ± 7.39 pg/ml (p = 0.006)
and an increase in body mass index (BMI) from 29.6 ± 4.5
to 31.0 ± 4.4 (p = 0.033) were found.
Table 2 Comparison of selected parameters in patients
with DCM from group A (atorvastatin group) and group B
(without statin) after 5-year follow-up
PARAMETER Group A (n = 22) Group B (n = 23) p
Mean ± SD Mean ± SD
BMI 28.9 ± 4.3 31.0 ± 4.4 ns*
Waist circumference (cm) 98.3 ± 12.9 96.9 ± 13.5 ns
Systolic RR (mm Hg) 114.7 ± 13.0 117.5 ± 7.7 ns
Diastolic RR (mm Hg) 71.5 ± 7.7 77.3 ± 5.3 ns
Heart rate 77 ± 9 69 ± 4 ns
Biochemical parameters
White blood cells (*103/μl) 6.9 ± 1.4 7.3 ± 1.4 ns
Hemoglobin (g/dl) 14.6 ± 1.4 14.5 ± 1.3 ns
Na (mmol/l) 138 ± 4 138 ± 3 ns
K (mmol/l) 4.4 ± 0.4 4.5 ± 0.5 ns
Total cholesterol (mg/dl) 178 ± 69 202 ± 30 0.02
HDL cholesterol (mg/dl) 52 ± 18 48 ± 9 ns
LDL cholesterol (mg/dl) 78 ± 25 123 ± 27 0.001
Triglycerides (mg/dl) 201 ± 212 153 ± 37 ns
ASPAT (U/l) 23.6 ± 6.3 26.2 ± 9.6 ns
ALAT (U/l) 23.5 ± 7.4 26.3 ± 10.7 ns
Urea (mg/dl) 30.80 ± 14.00 39.33 ± 7.84 ns
Creatinine (mg/dl) 0.92 ± 0.27 1.00 ± 0.32 ns
Uric acid (mg/dl) 5.28 ± 0.48 6.53 ± 0.46 0.001
CRP (mg/l) 1.4 ± 1.1 2.7 ± 2.5 ns
GRF MDRD (ml/min) 792 ± 22 71 ± 19 ns
Biomarkers
NT-proBNP (pg/ml) 1098.00 ± 1483.86 1151.24 ± 1371.00 ns
TNF-alpha (pg/ml) 19.10 ± 6.40 27.53 ± 7.39 0.001
Interleukin 6 (pg/ml) 14.90 ± 4.70 19.00 ± 3.94 0.01
Syndecan 4 (ng/ml) 4.40 ± 3.10 5.21 ± 4.00 ns
Cystatin C (mg/l) 1.17 ± 0.39 1.00 ± 0.18 ns
TGF-beta (pg/ml) 470.19 ± 166.50 463.00 ± 156.78 ns
Echocardiographic parameters
LVdD (cm) 6.6 ± 0.8 6.4 ± 1.8 ns
LVsD (cm) 5.1 ± 0.9 5.1 ± 1 ns
LVEF (%) 38.4 ± 8.8 33.9 ± 11.5 ns
LA diameter (cm) 4.7 ± 0.8 8.0 ± 10.5 ns
RVdD(cm) 2.9 ± 0.4 3.0 ± 0.6 ns
LVEdV (ml) 187.0 ± 37.0 191.6 ± 72.9 ns
LVsV(ml) 118.9 ± 41.0 104.0 ± 41.5 ns
TEI index 0.7 ± 0.2 0.5 ± 0.4 ns
Mitral regurgitation
dP/dT (mmHg/s)
569.5 ± 294.1 392.5 ± 83.0 ns
Table 2 Comparison of selected parameters in patients
with DCM from group A (atorvastatin group) and group B
(without statin) after 5-year follow-up (Continued)
Clinical state of patients
6-MWT (m) 419.3 ± 116.0 376.7 ± 114.3 ns
NYHA class (No. of patients [%])
I 1 (5) 3 (13) ns
II 12 (54) 10 (44)
III 8 (36) 7 (30)
IV 1 (5) 3 (13)
* ns – not statistically significant.
ABBREVIATIONS: 6 MWT 6-minute walk test; BMI body mass index; Na
sodium; K potassium; HDL high-density lipoprotein; LDL low-density
lipoprotein; ASPAT aspartate transaminase; ALAT alanine transaminase; CRP
C-reactive protein; NT-proBNP N-terminal pro-brain natriuretic peptide; TNF
tumor necrosis factor; TGF beta–transforming growth factor beta; GFR MDRD
glomerular filtration rate using modification of diet in renal disease formula;
LVdD left ventricular diastolic diameter; LVsD left ventricular systolic diameter;
LVEF left ventricular ejection fraction; LA left atrium; RVdD right ventricular
diastolic diameter; LVEdV left ventricular end-diastolic volume; LVsV left
ventricular systolic volume; NYHA; New York heart association.
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No patients had symptoms of myopathy. There were no
significant changes in aminotransferases activities be-
tween investigated groups of patients.Hospitalization and survival assessment
The following factors influenced the risk of HF hospitali-
zations on the basis of single-factor logistic regression:
leg edema, hepatomegaly, no beta-blocker therapy, NT-
proBNP, LVEF, LVsD and result of the 6-MWT (Table 3).
On the basis of single-factor logistic regression statistical
analysis we found that: no statin therapy, leg edema,
hepatomegaly, no beta-blocker therapy, renal failure, re-
hospitalizations, lower BMI, LVEF, higher NT-proBNP,
LVsD, LVdD, MR degree, significantly influenced the risk
of death (Table 4).
The survival of patients was 87.7% (95%CI: 79.2–96.2%),
67.9% (95%CI: 55.7–80.2%), and 63.1% (95%CI: 50.0–
76.2%) after 1, 2, and 5 years, respectively (Figure 1). Based
on a comparison of curves using the log-rank test, the
probability of survival to 5 years was significantly higher
in the group taking a low dose of statin (p = 0.005; hazard
ratio [HR] 3.48; 95%Cl 1.42–8.56) (Figure 2).
According to the multivariate regression analysis we
found that NT-proBNP (odds ratio [OR] 1.00, p = 0.007)
and LVdD (OR 2.96, p = 0.025) were the independent risk
factors of death, and 6-MWT (OR 0.99, p = 0.001) was the
only independent risk factors of re-hospitalization for
worsening heart failure. On the basis of ROC curve ana-
lysis we found that NT-proBNP values ≥1826 pg/ml, LVEF
≤30%, BMI ≤25.5, and MR ≥1.5 were significant predictors
of both re-hospitalization and increased mortality in this
group of patients.
Table 3 Predictors of re-hospitalizations in single-factor logistic regression
Categorical variable With re-hospitalization (%) Without re-hospitalization (%) p
leg edema 91 9 0.009
hepatomegaly 88 11 0.03
No beta-blocker therapy 98 0 0.006
Quantitative variable With re-hospitalization (median; Q25–Q75) Without re-hospitalization (median; Q25–Q75) p
BMI 2* 25; 24–30 30; 26–32 0.04
NT-proBNP 1 1848; 931–3248 895; 511–2026 0.02
NT-proBNP 2 1852; 775–4000 745; 360–1680 0.005
LVEF 1 27; 22–31 33; 28–38 0.02
LVEF 2 30; 24–32 34; 29–40 0.02
LVsD 2 6; 5.2–6.4 5.3; 4.4–5.6 0.001
MR 1 1.5; 1–2 1; 0–1 0.03
MR 2 1; 1–2 1; 0–1 0.03
6-MWT 1 350; 290–405 438; 350–490 0.01
6-MWT 2 370; 290–450 480; 395–595 0.001
*1 – for variables assessed after inclusion; 2 – for variables assessed after 2 months.
Q25–Q75: quartiles 25% and 75%.
ABBREVIATIONS: BMI body mass index; NT-proBNP N-terminal pro-brain natriuretic peptide; LVEF left ventricular ejection fraction; LVsD left ventricular systolic
diameter; MR mitral regurgitation; 6 MWT 6 minute walk test.
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Statins act by inhibiting the enzyme 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase, a
key step in the synthesis of cholesterol. The pleiotropic
effects of statins may be connected with this basic mech-
anism. In this mechanism, not only the synthesis ofTable 4 Predictors of death in single-factor logistic regression
Categorical variable Death (%)
No statin treatment 78
Leg edema 72
Hepatomegaly 66
No beta-blocker therapy 87.5
Renal failure 80
Re-hospitalizations 81
Quantitative variable With death (median; Q25–Q75)
BMI 1 24; 24–26
BMI 2 24; 23–26
NT-proBNP 1* 2771; 1500–5013
NT-proBNP 2 2900; 1296–4421
LVEF 1 27; 21–29
LVEF 2 30; 22–31
LVsD 2 6.2; 5.3–6.7
LVdD 2 7.6; 6.7–8.4
MR 1 2; 1–3
MR 2 2; 1–3
*1 – for variables assessed after inclusion; 2 – for variables assessed after 2 months
Q25–Q75: quartiles 25% and 75%.
ABBREVIATIONS: BMI body mass index; NT-proBNP N-terminal pro-brain natriuretic
diameter; LVdD left ventricular diastolic diameter; MR mitral regurgitation.cholesterol is reduced, but also that of the derivatives of
mevalonic acid, including isoprenoids. These compounds
participate in protein isoprenylation that links lipid frag-
ments with intracellular proteins [23]. In limiting the pro-
duction of isoprenoids, statins block the function of



















peptide; LVEF left ventricular ejection fraction; LVsD left ventricular systolic
Figure 1 Kaplan-Meier curves probability of survival in patients with DCM after 5-year follow-up. *DCM – dilated cardiomyopathy.
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increased angiogenesis and myocardial perfusion, decreased
myocardial apoptosis, and improvement in endothelial and
cardiac function [24]. The deteriorating circulatory insuffi-
ciency is characterized by an increased amount of free
radicals, which may inactivate nitric oxide (NO) [25,26].
Therefore, additional advantages of Rho protein inhibition
are also connected with increased endothelial synthesis of
NO and reduced expression of endothelin-1, which has a
positive effect on endothelial function [25,26]. In addition,
statins inhibit the synthesis of inflammatory cytokines andFigure 2 Probability of 5-year survival in patients with DCM treated achemokines, improve autonomic function, and reverse
myocardial remodeling [27,28].
Because of the pleiotropic effect of statins, there have
been attempts to use these drugs in the treatment of
DCM of nonischemic etiology. The present prospective,
randomized study evaluated the effects of a small atorva-
statin dose in 5-year observation on the parameters of
inflammation, left ventricular function, hospitalizations
and mortality in CHF patients with DCM who have
already received standard HF therapy. In the atorvastatin
group compared with the group without statin IL-6 andnd not treated with atorvastatin using Kaplan-Meier method.
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UA concentration was lower in the atorvastatin group
than in the group without statin therapy. No significant
differences concerning NT-proBNP concentration, echo-
cardiographic parameters of the left ventricle, distance
in the 6-min walk test and in functional classification
according to NYHA were observed between the exam-
ined groups. In the statin group after 5 years a decrease
in NT-proBNP concentration compared with initial
values and a decrease in LVdD and LVsD were achieved.
LVEF significantly increased also in the atorvastatin
group. Based on a comparison of curves using the log-
rank test, the probability of survival to 5 years is higher
in the group receiving a low dose of atorvastatin.
According to studies, hyperuricemia is an independent
prognostic marker in chronic and in acute heart failure
(AHF) [29,30]. Hyperuricemia can produce additional
adverse effects on the cardiovascular system and can
mediate the immune response [31,32]. Hyperuricemia in
patients with heart failure is associated with higher levels
of serum markers of inflammation (C-reactive protein
[CRP], IL-6, and neutrophil count) [33] and higher levels
of markers of endothelial activation, such as the soluble
intercellular adhesion molecule-1, and inflammatory
markers such as IL-6, TNF-α, and its receptors [34,35].
Although UA level has been associated with an increased
risk of cardiovascular events, it is unclear whether UA
can provide greater prognostic information than NT-
proBNP in advanced HF with nonischemic DCM. In the
study of Kim et al. UA and NT-proBNP values
were obtained from 122 DCM patients. Development of
clinical events during follow-up was defined as the com-
posite of cardiac death and readmission for heart failure.
During follow-up UA and NT-proBNP values were sig-
nificantly higher in patients with events. On multivariate
analysis, UA remained the only independent predictor
of prognosis [35]. The authors’ findings demonstrated
that UA value could be an informative predictor in
nonischemic DCM. In our study we observed lower UA
concentration in the group treated with atorvastatin,
which perhaps may be connected with better prognosis
in these patients. In DCM, an immunological component
may play a role, so immunomodulatory effects of statins
may be more advantageous. The study of Wojnicz et al.
[36] evaluated the safety, tolerability, and efficacy of statin
therapy in patients with heart failure secondary to inflam-
matory DCM and moderately elevated low-density lipo-
protein cholesterol levels. Seventy-four patients were
randomized to receive atorvastatin or conventional treat-
ment for HF. After 6 months of therapy, the predefined
primary efficacy end point (an increase of >5% in the ab-
solute left ventricular ejection fraction and ≥2 selected cri-
teria by echocardiography and a decrease in NYHA
functional class) was significant in the statin-treatedpatients (p = 0.004). Among secondary efficacy parame-
ters, the quality-of-life index showed a trend suggesting
the benefit of statin therapy. These results suggest a posi-
tive anti-inflammatory effect of atorvastatin in patients
with DCM. In the research of Gurguna et al. [37], the
effectiveness of 12 weeks’ therapy with fluvastatin,
80 mg/day, was assessed concerning the concentration of
inflammatory cytokines and LV function in patients with
cardiac insufficiency and DCM as well as with cardiac
insufficiency caused by coronary thrombosis. In both
groups, a considerable improvement of ventricular func-
tion and clinical symptoms of cardiac insufficiency was
achieved, as well as a decrease in the concentration of IL-6
and TNF-alpha [37]. In the study by Horwicha et al. [38],
statin therapy was related to a higher survival rate without
the necessity of urgent transplant in patients with cardiac
insufficiency of ischemic origin as well as of non-ischaemic
origin (91 vs 72%, p < 0.001 and 81 vs 63%, p < 0.001, re-
spectively) [38]. Sola et al. [39] evaluated the influence of
atorvastatin (20 mg/day) on vascular indicators of inflam-
mation and echocardiographic indicators in 89 patients
with dilated cardiomyopathy of nonischemic origin in
NYHA class II to IV, with LVEF <35%. In the group treated
with atorvastatin, considerable reduction of end diastolic
and end systolic volume of the LV was obtained compared
with the group treated with placebo [39]. In the statin
group they observed higher LVEF and a considerable de-
crease in the concentration of hsCRP, TNF-α receptor 2,
and IL-6, together with an increase of superoxide dismutase
(E-SOD) activity in erythrocytes, which meant that oxida-
tive stress and the inflammatory process decreased signifi-
cantly within the 12-month observation. A significant
improvement of clinical condition of patients in the atorva-
statin group was also observed (NYHA class in this group
2.2 ± 0.3 compared with 2.9 ± 0.3 in the placebo group,
p = 0.001) [39]. In the study by Node et al. [40], 53 pa-
tients with symptomatic DCM of nonischemic origin
(NYHA class II and III) with LVEF <40% were assigned
to a group receiving 10 mg of simvastatin or to a pla-
cebo group for 14 weeks. Patients treated with statin
had considerably lower functional class according to
NYHA and higher LVEF compared with patients from
the placebo group. The concentrations of TNF-alpha,
IL-6 and BNP were also significantly lower in the simva-
statin group. The results of our study showing de-
creased IL-6 and TNF-α concentrations are in accord
with Gurguna et al. [37], Horwich et al.[38], Sola et al.
[39] and Node et al. [40]. We also observed a decrease
in NT-proBNP concentration compared to initial values
and a decrease in LVdD and LVsD in the group treated
with atorvastatin.
On the other hand, Bleske et al. [41] randomly assigned
15 patients with DCM of nonischemic origin in functional
class I to III according to NYHA to a group treated with
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Although treatment was found to be safe and associated
with considerable reduction of LDL cholesterol, the authors
did not observe a significant difference between atorvastatin
and placebo concerning NT-proBNP, hsCRP, TNF-alpha
and indicators of endothelial activation: vascular adhesion
molecule-1, intracellular adhesive molecule-1 and P-
selectin [41]. In the study carried out by Krum et al. [42],
the influence of rosuvastatin 40 mg in 86 patients with
systolic heart failure (LVEF <40%) of ischemic or nonisch-
emic etiology was assessed (68 patients with DCM). The
primary end point was change in LVEF by radionuclide
ventriculogram. Secondary end points included changes in
echocardiographic parameters, neurohormonal and inflam-
matory markers, Packer composite score, death and HF
hospitalization. Despite being safe and effective at decreas-
ing plasma cholesterol, high-dose rosuvastatin did not
beneficially alter parameters of LV remodeling [42].
In our study we observed better survival in the atorva-
statin group of patients with DCM. The UNIVERSE and
CORONA studies using rosuvastatin showed no benefi-
cial effect on mortality in patients with mainly ischemic
chronic HF [11,12]. In the post-hoc analysis of the
Eplerenone Post-Acute Myocardial Infarction Heart
Failure Efficacy and Survival Study (EPHESUS) [43], the
initiation of statin therapy mainly during hospital stay
for acute HF complicating acute myocardial infarction
was associated with a lower risk of all-cause death. In a
post-hoc analysis performed in 6632 patients included in
the EPHESUS trial, 47% of patients had a statin pre-
scribed at baseline. During a mean follow-up of 16 ± 7
months, all-cause death occurred in 12% of patients tak-
ing and in 18% of patients not taking a statin (p < 0.001).
The risk of all-cause death was 20% lower in patients on
statin. The reduction of all-cause death appears to be
mainly attributable to a lower rate of cardiovascular
death, especially sudden death and stroke [43].
The GISSI-HF trial [13] is the only large prospective
study with some relevance to DCM because rosuvastatin
was examined in a mixed population with heart failure.
Rosuvastatin 10 mg/day did not affect clinical outcomes
(death, hospitalization for cardiovascular reasons) in pa-
tients with CHF of any cause. However, the number of
patients with DCM was small [13]. Treatment with
rosuvastatin was safe [13].
To determine whether statin therapy improves survival
in patients with heart failure secondary to nonischemic
DCM, data from 1024 patients (NYHA functional class
III and IV) with LVEF ≤0.35, who were enrolled in the
BEST (Beta-blocker Evaluation of Survival Trial) trial
were analyzed [44,45]. Statin therapy was independently
associated with decreased all-cause mortality (HR 0.38,
95%CI 0.18–0.82, p = 0.0134) and cardiovascular death
(HR 0.42, 95%CI 0.18–0.95, p = 0.037) [45]. Suddendeaths due to rapid ventricular arrhythmias account
for ~ 50–80% of all deaths in patients with idiopathic
DCM. This reduction of deaths might be caused, in part,
by a reduction in arrhythmic sudden death [46,47].
Confirmation of this thesis can be found in the study by
Xian-Zhi et al. [48], where early and intensive atorva-
statin therapy significantly decreased the recurrence of
ventricular premature beat or non-sustained ventricular
tachycardia.
The study by Buber et al. [49] was performed in a subset
of 821participants in the Multicenter Automatic Defibril-
lator Implantation Trial with Cardiac Resynchronization
Therapy (MADIT-CRT) trial with a diagnosis of heart fail-
ure other than ischemic. In this analysis of data covering
821 patients, 499 of them received statins. Multivariate
analysis showed that time-dependent statin therapy was
independently associated with a significant 77% reduction
in the risk of fast ventricular tachyarrhythmias (VT/VF)
or death (p < 0.001) and with a significant 46% reduction
in the risk of appropriate implantable cardioverter defibril-
lator shocks (p = 0.01). Consistent with these findings, the
cumulative probability of fast VT/VF or death at 4 years
of follow-up was significantly lower among patients who
were treated with statins (11%) as compared with study
patients who were not treated with statins (19%; p = 0.006
for the overall difference during follow-up). The study
demonstrated that the use of statins is associated with a
significant reduction in life-threatening arrhythmias in pa-
tients with nonischemic heart failure [49].
One of the potential explanations why recent pro-
spective studies using hydrophilic rosuvastatin have not
shown any beneficial effect on mortality [13,50-52] may
be connected with the observation that metabolic and
cardiac effects may differ between the lipophilic and
hydrophilic statins. It may be suggested that one of the
beneficial mechanisms of statins could be to rapidly affect
signaling pathways in cell membranes of the myocardium
and/or the autonomic nervous system, thereby protecting
patients from life-threatening arrhythmias. This assump-
tion would be in line with data showing statins to improve
autonomic neural control and increase electrical stability
of the myocardium [13,48-52]. The highly lipophilic statins
such atorvastatin and simvastatin become easily embedded
into the membrane, having overlapping locations in the
hydrocarbon core adjacent to the phospholipid head
groups [48]. Gao et al. reported that lipophilic simvastatin
therapy in pacing-induced CHF inhibited NADPH oxida-
tive activity in the rostral ventrolateral medulla and reduced
the central sympathoexcitatory response in association with
improvement in LV function [53]. Activation of the sym-
pathetic nerve system is one of the important prognostic
predictors for CHF patients [54]. Tsutamoto et al. ran-
domized 63 stable outpatients with DCM to atorvastatin
(n = 32) or rosuvastatin (n = 31) therapy. They evaluated
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dobenzylguanidine (MIBG) scintigraphy, hemodynamic pa-
rameters and neurohumoral factors before and after
6 months of treatment [55].
The level of plasma oxidized LDL (oxLDL), a bio-
marker of oxidative stress in the failing heart, is an inde-
pendent prognostic predictor in CHF patients [56]. The
clinical studies suggested that lipophilic statins improve
cardiac sympathetic activity by reducing oxidative stress
[57,58]. Mason et al. reported that the antioxidant ef-
fects of an active metabolite of atorvastatin were stron-
ger than those of rosuvastatin [59]. Therefore, the
increase in LVEF observed in the atorvastatin group
may be partly related to an improvement of the oxida-
tive stress in the myocardium. Li et al. [60] explored the
effect of early statin therapy (atorvastatin and simva-
statin) on mortality in patients with nonischemic DCM.
A total of 315 patients with nonischemic DCM were en-
rolled. The median follow-up period was 45.1 months.
By single-factor analysis, they found that the follow-up
mortality was 17% in the statin group and it was signifi-
cantly lower than the 37% mortality of non-statin users
(p = 0.003); in patients with worsening cardiac function
NYHA III-IV, the mortality of the statin group was 17%
while a much higher mortality of 47% was found in
non-statin users (p = 0.003). The authors concluded that
early treatment with atorvastatin or simvastatin was
closely correlated with the reduction of mortality in
nonischemic dilated cardiomyopathy patients, which is
consistent with our findings [60-62]. Our findings of
better survival in the atorvastatin group are consistent
with Vrtovec et al. [14], Domanski et al. [45] and Li
et al. [60] and may support the underlying mechanism
described by Buber et al. [49] and Tsutamoto et al. [55].
Our study has several limitations that include the rela-
tively small number of patients at 5-year follow-up. The
dose of statin after 2-month therapy in the atorvastatin
group was adjusted individually to 10 or 20 mg. The
open-trial methodology (not double-blinded study) need
to be considered as a study limitation.
In conclusion, the pleiotropic effects of atorvastatin in
a small dose (10–20 mg/day) significantly reduce levels
of inflammatory cytokines (TNF-α, IL-6) and uric acid,
as well as improve hemodynamic parameters (LVdD,
LVsD and LVEF) in DCM patients after 5 years of treat-
ment, and have a significant impact on the survival of
this group of patients.
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